Effect of liraglutide on interleukin-1β expression in the pancreatic islets of OLETF rats.
- Author:
Nanjing GUO
1
;
Jia SUN
;
Hong CHEN
;
Yanhua XU
;
Fei GAO
;
Hua ZHANG
;
Zhen ZHANG
;
Dehong CAI
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Blood Glucose; metabolism; Caspase 3; metabolism; Diabetes Mellitus, Experimental; metabolism; Glucagon-Like Peptide 1; analogs & derivatives; pharmacology; Insulin; secretion; Interleukin-1beta; metabolism; Islets of Langerhans; metabolism; Liraglutide; Male; Rats; Rats, Inbred OLETF
- From: Journal of Southern Medical University 2012;32(6):878-881
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of liraglutide on the inflammatory cytokine interleukin-1β (IL-1β) and apoptotic factor caspase-3 expression in the pancreatic islets of OLETF rats with impaired glucose tolerance.
METHODSTwelve-week-old OLETF rats were randomized into 4 groups and received intraperitoneal injections of saline or liraglutide at 50, 100, or 200 µg/kg twice daily for 12 weeks. Eight LETO rats served as the normal control group and received saline injection. After the treatments, the rats were examined for fasting and 30 min plasma insulin during OGTT test, and the expression levels of IL-1β and caspase-3 mRNA and protein in the pancreatic islets were detected by real-time PCR and Western blotting, respectively.
RESULTSCompared with the saline group, liraglutide significantly decreased the expressions of IL-1β and caspase-3 mRNA and protein, and significantly improved the blood glucose, islet β function and early-phase insulin secretion index in OLETF rats.
CONCLUSIONSLiraglutide can improve islet function and glucose metabolism partially by inhibiting islet IL-1β expression to delay or prevent the development of diabetes in OLETF rats.
